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Abstract
Islet autoimmunity in children who later progress to type 1 diabetes is preceded by dysregulated serum metabolite profiles,
but the origin of these metabolic changes is unknown. The gut microbiota affects host metabolism and changes in its
composition contribute to several immune-mediated diseases; however, it is not known whether the gut microbiota is
involved in the early metabolic disturbances in progression to type 1 diabetes. We rederived non-obese diabetic (NOD) mice
as germ free to explore the potential role of the gut microbiota in the development of diabetic autoimmunity and to
directly investigate whether the metabolic profiles associated with the development of type 1 diabetes can be modulated
by the gut microbiota. The absence of a gut microbiota in NOD mice did not affect the overall diabetes incidence but
resulted in increased insulitis and levels of interferon gamma and interleukin 12; these changes were counterbalanced by
improved peripheral glucose metabolism. Furthermore, we observed a markedly increased variation in blood glucose levels
in the absence of a microbiota in NOD mice that did not progress to diabetes. Additionally, germ-free NOD mice had a
metabolite profile similar to that of pre-diabetic children. Our data suggest that germ-free NOD mice have reduced
glycaemic control and dysregulated immunologic and metabolic responses.
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Introduction
Type 1 diabetes is an autoimmune disorder characterized by the
specific destruction of insulin-producing beta cells in the pancreas
[1]. The incidence of type 1 diabetes among children and
adolescents has increased markedly in western countries in recent
decades [2]. In contrast to other autoimmune diseases with a clear
female bias, type 1 diabetes has no clear gender separation in
children and has a male bias in young adults [3]. Genetic risk
factors affect disease incidence; however, less than 10% of the
individuals carrying human leukocyte antigen (HLA) risk alleles
develop diabetes and the concordance between monozygotic twins
is less than 40%, suggesting that environmental factors are
important for disease development [4,5]. Infections as well as
dietary factors have been implicated as triggers of autoimmunity
and disease progression [6] and, according to the hygiene
hypothesis, infections early in life could prevent allergic diseases
[7]. Despite promising results in rodent models, clinical trials to
treat type 1 diabetes using immunotherapy such as anti-CD3
monoclonal antibodies or cytotoxic T lymphocyte antigen-
immunoglobulin (CTLA4-Ig) have only shown a partial improve-
ment of the disease [8–10]. Recent trials using haematopoietic
stem cell transplantation as a treatment of type 1 diabetes have
shown promising results but it is still unclear whether it can safely
be used to treat all patients [8]. Thus, there is still a need to
identify new factors that trigger type 1 diabetes that may be
targeted in treatment of the disease.
The gut microbiota is a complex microbial ecosystem that is
considered to be a major driving force in immunological
maturation [11]. Its profound role in regulating host metabolism
has become evident in recent years [12] and emerging evidence
indicates that it is a possible modulator of diabetes. Several reports
have demonstrated that an altered microbiota is associated with
risk of developing type 2 diabetes [13,14] and both preclinical and
clinical type 1 diabetes [15,16]. Furthermore, maternal use of
phenoxymethyl or quinolone antimicrobials before pregnancy is
associated with an increased risk of type 1 diabetes in the offspring
[17,18]. Studies in non-obese diabetic (NOD) mice suggest a direct
involvement of the gut microbiota in the development of
autoimmune diabetes [19,20]. However, the mechanisms that
PLOS ONE | www.plosone.org 1 November 2014 | Volume 9 | Issue 11 | e110359
link the microbiota with autoimmune disease remain to be
determined.
A recent report suggested that microbially driven increases in
testosterone levels can explain the relative protection against
diabetes observed in male NOD mice [21]. However, because
puberty does not confer protection against type 1 diabetes in men
[3], it is unclear whether this microbially derived effect is present
in humans and suggests that there are additional effects of the
microbiota on type 1 diabetes development that are not gender
dependent.
Changes in the microbiota have been shown to affect the
metabolome of the host and our previous metabolomics study
revealed that metabolic abnormalities precede islet autoimmunity
in children who later progress to type 1 diabetes independent of
HLA-associated genetic risk [22]. We also showed that lipidomic
profiles of children who progress to type 1 diabetes are similar to
those of female NOD mice [23]. Here we rederived NOD mice as
germ free (GF) to investigate the microbial influence on diabetic
autoimmunity and to directly investigate whether the metabolic
profiles associated with the development of type 1 diabetes can be
modulated by the gut microbiota.
Materials and Methods
Mice
GF NOD mice were rederived at Taconic farms and were
thereafter maintained in flexible plastic film isolators under a strict
12-h light cycle (lights on at 06:00 h) at the University of
Gothenburg. GF status was verified regularly by anaerobic
culturing in addition to PCR for bacterial 16S rDNA. Both GF
and conventionally raised (CONV-R) NOD mice were fed
autoclaved chow diet (Labdiet) ad libitum. Diabetes incidence
was determined by monitoring blood glucose levels weekly by
sampling of a small volume of blood from the tail vein. Mice were
considered diabetic when values exceeded 18 mM for two
consecutive weeks or 25 mM for one week. Blood for metabo-
lomics and cytokine analyses was collected from the vena cava at
the termination of the experiment under deep isoflurane
anesthesia after a 4 h fast, unless otherwise stated. This study
was carried out in accordance with the recommendations for
Laboratory Animals in Sweden. The protocol was approved by the
Committee on the Ethics of Animal Experiments at the University
of Gothenburg (Permit Number: 338–2012). All efforts were made
to minimize animal suffering.
Insulitis and beta cell area
Sections 200–300 mm apart from the pancreas of 4-, 9- and 23-
week-old mice were stained with haematoxylin and eosin and
scored according to the following criteria: no infiltration (0); peri-
insulitis (1); #50% destruction of islet (2); $50% destruction of
islet (3). We scored 100 (at 4 and 9 weeks) and 50 (at 23 weeks)
islets per mouse. For beta cell area, sections 300 mm apart through
the whole pancreas were stained with guinea pig anti-insulin
(Dako), visualized using VECTASTAIN ABC and Vulcan Fast
Red Chromogen Kit 2 (Histolab), and counterstained with
haematoxylin. The area stained for insulin was compared with
the total area of the tissue using Biopix software.
Insulin autoantibodies
Serum insulin autoantibodies (IAA) were analysed using a
competitive radiobinding assay as previously described [15]. The
results were expressed in relative units (RU) based on standard
curves run on each plate. The cut-off value for mouse IAA
positivity was set at the mean+3SDS in 29 BALB-mice, i.e. 0.88
RU.
Cytokine measurements
Serum from mice at 15 and 23 weeks was analysed with
Mesoscale 9-plex cytokine assay according to the manufacturer’s
instructions.
Oral glucose tolerance test (OGTT) and insulin
measurements
Mice aged 17–18 weeks were fasted for 4 h and orally gavaged
with 20% D-glucose (2 g/kg). Blood was drawn from the tail vein
at 0, 15, 30, 60, 90 and 120 min and blood glucose levels were
measured using a HemoCue glucometer. Insulin levels were
measured at 0, 15 and 30 min after gavage. In mice that did not
progress to diabetes by 30 weeks of age, insulin levels were
measured after a 4 h fast. Insulin was measured using insulin
ELISA-kit (Crystal Chem).
Analysis of polar metabolites by GC6GC-TOFMS
An established metabolomics platform using two dimensional
gas chromatography coupled to time-of-flight mass spectrometry
(GC6GC-TOFMS) was used to analyse polar metabolites in
serum [24]. Serum samples (30 ml) were combined with 10 ml of an
internal standard, labelled palmitic acid (16:0–16,16,16d3;
500 mg/l), and 400 ml of methanol, vortexed for 2 min and
incubated for 30 min at room temperature. The supernatant was
separated by centrifugation at 5590 g for 5 min at room
temperature. The sample was dried under a constant flow of
nitrogen. Twenty-five ml of 2% methoxyamine hydrochloride in
pyridine was added to the dried sample and incubated at 45uC for
1 h and then derivatized with 25 ml of N-methyl-N-(trimethylsilyl)-
trifluoroacetamide by incubating at 45uC for 1 h. Five ml of
retention index standard mixture with five alkanes (400 mg/l) was
added to the metabolite mixture. Sample order for analysis was
established by randomization. The samples were analysed on a
Leco Pegasus 4D GC6GC-TOF mass spectrometer with Agilent
technologies 6890N GC and Combi PAL autosampler. Data were
processed using the Guineu software [24].
Analysis of molecular lipids by UPLC-MS
An established platform based on Acquity Ultra Performance
LC coupled to time-of-flight mass spectrometry (UPLC-MS) was
used to analyse the molecular lipids in aliquots (10 ml) of serum
samples [25]. The data were processed using MZmine 2 software
[26] and the lipid identification was based on an internal spectral
library or on de novo identification using tandem MS [25].
Statistical analysis
Data were analysed by Student’s t test and presented as mean6
SEM or SD. Survival curves were analysed with log-rank (Mantel-
Cox) test. IAA positivity was analysed by Fisher’s exact test.
Univariate statistical analysis of metabolomics data used MA-
TLAB r2012a. Clustering was performed and visualized using the
MeV software [27].
Results
Colonization status affects insulitis and the presence of
IAA in NOD mice
To investigate the potential role of the gut microbiota in the
development of type 1 diabetes, we rederived NOD mice as GF.
Female NOD mice developed diabetes at a higher rate and at an
Microbiota and T1D
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earlier time point than male NOD mice (Fig. 1A), in agreement
with a previous report [28]. Disease onset was earlier in GF
compared with CONV-R male NOD mice but no difference was
observed between female GF and CONV-R NOD mice (Fig. 1A).
There was no significant difference between diabetes progression
of GF and CONV-R NOD mice (both male and female) by 30
weeks (Fig. 1A).
To further investigate autoimmunity in the NOD mice, we
investigated the rate of islet infiltration (Fig. 1B). At 9 weeks, there
was a tendency towards enhanced insulitis in male GF NOD mice
and a significant increase in insulitis in female GF NOD mice
compared with their CONV-R NOD counterparts (Fig. 1C, D).
The difference in rate of infiltration was only transient since there
was no difference in insulitis score between GF and CONV-R
NOD mice that had not yet progressed to diabetes at 23 weeks
Figure 1. Diabetes incidence and insulitis in NOD mice. (A) Cumulative diabetes incidence in male and female GF and CONV-R mice. (B)
Representative images of islets in four insulitis categories: 0 (no infiltration); p.i. (peri-insulitis); ,50% destruction; .50% destruction. Scale bar
represents 100 mm. (C, D) Distribution of islet scores and average insulitis score in GF and CONVR male (C) and female (D) mice at 4, 9 and 23 weeks
(n = 6–7). Data are presented as mean 6 s.e.m. **p,0.01 determined by Student’s t-test.
doi:10.1371/journal.pone.0110359.g001
Microbiota and T1D
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(Fig. 1C, D). In addition, we did not observe any differences in
beta cell area of the pancreas in female NOD mice at 23 weeks
(Fig. S1).
We observed that GF NOD mice were significantly more likely
to be positive for IAA compared with CONV-R NOD mice at 4
weeks (Table 1) and autoantibody titers were higher in GF
compared with CONV-R NOD mice at 9 weeks (Fig. S2).
Colonization status affects serum cytokine levels
To analyse potential changes in immunological parameters in
response to the absence of microbiota, we analysed interleukin 10
(IL-10), interferon gamma (IFN-c) and interleukin 12 (IL-12). At
15 weeks, IL-10 levels were higher in GF versus CONV-R male
NOD mice, but no differences were noted for IFN-c and IL-12
(Fig. 2A–C). However, at 23 weeks, levels of IFN-c and IL-12
were significantly higher in male and female GF NOD mice
compared with their CONV-R counterparts (Fig. 2B, C) and IL-
10 levels were reduced in female CONV-R mice (Fig. 2A).
Improved peripheral glucose metabolism in GF NOD
mice
We hypothesized that peripheral glucose metabolism is
improved in NOD mice lacking a microbiota, which may partly
explain why we did not observe an increased rate of diabetes
incidence in GF NOD mice despite an increase in IAA and pro-
inflammatory cytokines compared with CONV-R NOD mice. At
30 weeks, fasting glucose levels were not different between GF and
CONV-R non-progressing male NOD mice, but fasting insulin
levels were lower in the GF mice (Fig. 3A, B), indicating an
improved peripheral glucose metabolism similar to GF wild-type
mice on different genetic backgrounds [29,30]. We also performed
an OGTT in GF and CONV-R NOD mice at 17–18 weeks of age
(in the total group, i.e. both non-progressors and progressors). We
observed a faster glucose clearance in GF versus CONV-R female
NOD mice and a tendency towards improved glucose tolerance in
GF versus CONV-R male NOD mice (Fig. S3). Insulin levels after
an OGTT were not different between GF and CONV-R NOD
mice (Fig. S3), indicating that the improved glucose clearance in
GF NOD mice was not due to enhanced insulin secretion.
Dysregulation of blood glucose in non-progressing GF
NOD mice
Although we did not see any difference in diabetes incidence
between GF and CONV-R NOD mice, we observed striking
differences when we analysed the non-fasting blood glucose levels
in the mice that did not progress to diabetes by 30 weeks of age
(Fig. 3C–H). At 12 weeks, blood glucose levels were lower in non-
progressing GF NOD male mice compared with their CONV-R
counterparts (Fig. 3C). However, from 20 weeks, blood glucose
levels were significantly higher in non-progressing GF compared
with CONV-R NOD mice (Fig. 3C, D). The mean blood glucose
levels and the percent relative standard deviation (%RSD) in blood
glucose levels per mouse from 12–30 weeks were higher in non-
progressing GF compared with CONV-R NOD mice (Fig. 3E–H),
Table 1. Proportion of insulin autoantibody (IAA)-positive mice in relation to age.
Age P value
GF CONV-R
4 weeks 76.5% (n = 17) 38.9% (n = 18) 0.041
9 weeks 92.9% (n = 14) 61.9% (n = 21) 0.056
23 weeks 90% (n = 20) 75% (n = 16) 0.374
Analysis of serum samples of germ-free (GF) and conventionally raised (CONV-R) NOD mice. Data were analyzed by Fisher’s exact test.
doi:10.1371/journal.pone.0110359.t001
Figure 2. Altered serum levels of pro- and anti-inflammatory
cytokines in GF NOD mice. Serum levels of IL-10 (A), interferon
gamma (B) and IL-12 (C) in male and female mice at 15 and 23 weeks.
Data are presented as mean 6 s.e.m. *p,0.05, **p,0.01, ***p,0.001
GF vs CONV-R mice determined by Student’s t-test. (Female: 15 weeks
n = 9; 23 weeks n = 5. Male: 15 weeks n = 6; 23 weeks n = 7.).
doi:10.1371/journal.pone.0110359.g002
Microbiota and T1D
PLOS ONE | www.plosone.org 4 November 2014 | Volume 9 | Issue 11 | e110359
further demonstrating the decrease in blood glucose control in
both male and female GF NOD mice.
Colonization status affects the serum metabolic profile in
NOD mice
To investigate whether the early metabolic abnormalities
preceding islet autoimmunity in children who progressed to type
1 diabetes observed in a previous human study [22] might be
modulated by the gut microbiota, we performed global metabo-
lomic analysis of serum taken from GF and CONV-R NOD mice
(both non-progressors and progressors to autoimmune diabetes).
Two analytical platforms with broad analytical coverage were
applied to all samples: (1) a global lipidomics platform based on
UPLC-MS, which covers molecular lipids such as phospholipids,
sphingolipids, and neutral lipids; and (2) a platform for global
profiling of small polar metabolites based on comprehensive two-
dimensional GC6GC-TOFMS, which covers small molecules
such as amino acids, free fatty acids, keto-acids, various other
organic acids, sterols, and sugars. A total of 358 molecular lipids
and 195 polar metabolites were detected and included in the
analysis. When observing the significantly altered metabolites in
young mice, we found that the colonization status was the
dominant factor that affected the clustering of metabolic profiles
(Fig. 4), in agreement with recent findings by Markle et al. [21].
Figure 3. Altered blood glucose control in GF NOD mice. (A,B) Fasting blood glucose (A) and insulin levels (B) in male non-progressing mice 30
weeks of age. (C,D) Non-fasting blood glucose levels in non-diabetic male (GF n = 12, CONV-R n = 14) (C) and female (GF n = 9, CONV-R n = 5) (D) mice
from 12–30 weeks. (E–H) Average blood glucose levels per mouse and percent relative standard deviation (RSD) of glucose values per mouse from
12–30 weeks in male (E,F) and female (G,H) mice. Data are presented as mean 6 s.e.m. (A, B, E–H) or mean 6 s.d. (C,D). *p,0.05, **p,0.01, ***p,
0.001 vs CONV-R mice determined by Student’s t-test.
doi:10.1371/journal.pone.0110359.g003
Microbiota and T1D
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Within the GF and CONV-R groups, we observed subclustering
by age and gender (Fig. 4).
The colonization status had a similar effect on metabolic profiles
of 4- and 9-week-old mice (r = 0.52, P,0.001, for the associations
of CONV-R/GF fold changes in 4- and 9-week old mice for the
156 significantly different metabolites). As expected, the metabo-
lites of similar structural class tended to co-cluster (Fig. 4), thus
allowing for comparison of metabolic profiles at the class level. GF
NOD mice had reduced levels of tricarboxylic acid (TCA) cycle
metabolites, sugar derivatives and triglycerides compared with
CONV-R mice (Fig. 4). Furthermore, branched chain amino
acids (BCAAs) were elevated at 9 and 23 weeks in male GF NOD
mice and at 4 and 9 weeks in female GF NOD mice (Figs. 4, 5).
There was also an elevated cluster of metabolites in the profile of
GF NOD mice that consisted primarily of amino acids including
glycine, phenylalanine, tyrosine and 2-hydroxybutyric acid
(Fig. 4).
We previously observed that differences between the cord serum
metabolomes of newborn infants who progress to type 1 diabetes
and their controls are similar to differences found between the 9-
week-old GF and CONV-R Swiss Webster mice [31]. To
determine whether these similarities were also observed in the
NOD mice, we compared previously acquired human data from
15 type 1 diabetes progressors and 24 controls [22] with the
metabolomics dataset from 9-week-old GF and CONV-R NOD
mice. Triglycerides were excluded from the comparison due to
high variability in the clinical dataset. A total of 53 lipids and 25
polar metabolites were matched across the datasets. We found that
the difference in the metabolome of type 1 diabetes human
progressors compared with controls significantly correlated with
that of GF compared with CONV-R NOD mice (r = 0.43,
P = 7.061025, comparing mean concentrations of each of the 78
metabolites in type 1 diabetes progressors and GF mice, scaled by
mean concentrations in non-progressors and CONV-R mice,
respectively).
Discussion
Here we identified a profound role of the gut microbiota in the
regulation of glycaemic control as well as of immunological and
metabolic profiles in a mouse model of autoimmune diabetes. The
absence of gut microbiota in NOD mice did not affect overall
disease incidence, but resulted in increased insulitis and levels of
IAA and pro-inflammatory cytokines, and worsened glucose
control in mice that did not progress to diabetes. Furthermore,
we observed differences in the serum metabolomic profiles
between GF and CONV-R NOD mice that resembled the
difference between those of newborn infants who later progress to
type 1 diabetes and non-progressors, suggesting that the
metabolomic changes in infants who later progress to type 1
diabetes may be modulated by the gut microbiota.
The similarity in diabetes incidence in both male and female
mice between GF and CONV-R NOD is in agreement with
earlier studies [21,32]. We observed an increase in insulitis in GF
NOD mice at 9 weeks, again consistent with previous results [32],
but the effect was only transient and there was no difference in
beta cell area in older mice. Disease incidence is affected by
housing conditions [33] and the relatively high disease incidence in
our CONV-R mice could be explained by the clean housing
conditions in our specific pathogen free facility. IAA positivity was
more frequent at 4 weeks of age in GF versus CONV-R NOD
mice, which may mirror progressive beta cell autoimmunity [34]
and contribute to the enhanced beta cell destruction indicated by
the increased insulitis at 9 weeks. The gut microbiota is known to
affect B-cell development [35] and B-cells have been shown to be
important contributors to diabetes progression in the NOD mouse
model [36]. However, the difference in IAA production from B-
cells did not contribute to an effect on overall diabetes incidence.
We observed that levels of IFN-c and IL-12 were higher in GF
compared with CONV-R NOD mice at 23 weeks in both male
and female mice. These cytokines are known to influence diabetes
progression in NOD mice [37], and IL-12-induced secretion of
IFN-c at the effector stage of diabetes development has previously
been shown to promote diabetes in NOD mice [38,39]. The
increase in IL-12 and IFN-c at 23 weeks was paralleled by an
increase in autoantibody titers in GF NOD mice, consistent with
an association between these cytokines and autoimmunity. In
addition, we observed a decrease in IL-10 levels in female CONV-
R at 23 weeks of age. IL-10 has been shown to protect against
diabetes in NOD mice but only when administered from an early
age [40], and thus the reduction in IL-10 levels we observed might
not have an influence on autoimmunity.
Earlier studies have shown that GF wild-type mice have
improved peripheral glucose metabolism compared with their
CONV-R counterparts [30]. We therefore tested the hypothesis
that the incidence of diabetes is similar in GF and CONV-R NOD
mice because improved peripheral glucose metabolism counter-
balances the increased autoimmunity in GF NOD mice. In
agreement with our hypothesis, we showed that fasting insulin
levels in NOD mice that had not progressed to diabetes by 30
weeks were lower in GF versus CONV-R mice despite similar
fasting glucose levels. Furthermore, female GF NOD mice had
improved glucose clearance at 17–18 weeks. We propose that the
GF NOD mice are more resistant to developing diabetes because
lower levels of insulin are required to maintain normoglycaemia in
these mice. However, the blood glucose levels of the GF NOD
mice that had not progressed to diabetes by 30 weeks increased
after 20 weeks of age with considerably higher variability
compared with CONV-R NOD mice in both male and female
mice, suggesting that blood glucose control in the non-fasting state
is reduced in GF NOD mice.
We observed differences in the global profiles of polar
metabolites and molecular lipids between 9-week-old GF and
CONV-R NOD mice that were similar to those reported earlier
between GF and CONV-R Swiss Webster mice [31]. Specifically,
as previously seen in GF wild-type Swiss Webster mice, GF NOD
mice had reduced levels of TCA cycle metabolites, sugar
derivatives and triglycerides compared with their CONV-R
counterparts. However, in contrast to an increase in only one
BCAA (valine) in GF versus CONV-R Swiss Webster mice [31],
we observed an increase in all three BCAAs (isoleucine, valine and
leucine) in GF versus CONV-R NOD mice irrespective of gender.
Increased levels of BCAAs predict both type 1 and 2 diabetes
[22,41,42] and have been shown to contribute to insulin resistance
[43]. An abnormal insulin response caused by increased levels of
Figure 4. Heatmap of significantly altered identified metabolites in GF and CONV-R NOD mice in 4- and 9-week old mice. For each
metabolite, the levels in each mouse are normalized to the mean level in CONV-R mice, i.e., yellow and blue indicate increased and decreased levels
of the metabolites, respectively, relative to the average level in CONV-R mice. Hierarchical clustering is applied across all metabolites (performed
across all n = 69 samples analyzed) and all mice. (Female n = 6–10. Male n = 7–11.).
doi:10.1371/journal.pone.0110359.g004
Microbiota and T1D
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BCAAs could thus potentially explain the reduced glycaemic
control in GF NOD mice.
We also observed an increase in the amino acids glycine,
phenylalanine, tyrosine and 2-hydroxybutyric acid in GF versus
CONV-R NOD mice, which was not seen in the previous study in
GF versus CONV-R Swiss Webster mice [31]. These metabolites
are associated with progression to insulin resistance and type 2
Figure 5. Increased levels of branched chain amino acids in GF NOD mice. Relative concentrations of branched chain amino acids mice at 4,
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diabetes [41,42,44] but it is unclear whether they also affect beta
cell function.
The differences in the metabolic profiles between GF and
CONV-R NOD mice in our study correlated significantly with
differences in the metabolic profiles between newborn infants who
later progressed to type 1 diabetes and non-progressors from a
previous study [22]. Notably, elevated insulinotropic BCAAs and
diminished TCA cycle metabolites had been observed in these pre-
diabetic children even before the first seroconversion for islet
autoantibodies [22]. These results indicate that the changes in
metabolic profiles in infants who later progress to type 1 diabetes
could be microbially driven.
In our study, the effects of the microbiota in NOD mice were
similar in males and females and thus not likely to be dependent
on testosterone levels, in contrast to previous results that identified
a gender-dependent protective effect of the microbiota in NOD
mice [21]. This is of importance because type 1 diabetes does not
have a female bias in humans [3] and suggests that there are
microbial effects in addition to those mediated by sex hormones
that may protect against autoimmune diabetes.
In conclusion, our results support a role of the gut microbiota as
a regulator of diabetic autoimmunity and glucose metabolism and
suggest that altered microbial metabolism may contribute to the
pathogenesis of type 1 diabetes.
Supporting Information
Figure S1 Beta cell area in 23 week old NOD mice.
Insulin area as a percent of total pancreas area was measured in
female mice at 23 weeks (n = 6 per group). Data are presented as
mean 6 s.e.m.
(EPS)
Figure S2 Altered IAA titers in GF NOD mice. Scatter plot
of relative IAA units (4w GF n= 17, CONV-R n= 18; 9w GF
n=14, CONV-R n= 21; 23w GF n= 20, CONV-R n= 16). Line
represents median value **p,0.01 determined by Student’s t-test.
(EPS)
Figure S3 Glucose tolerance in GF NOD mice. Oral
glucose tolerance test, average area under the curve (AUC) and
serum insulin levels in GF and CONV-R mice at 17–18 weeks of
age (n = 4–5). Data are presented as mean 6s.e.m. *p,0.05
determined by Student’s t-test.
(EPS)
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